Phaseline

Companies › Enliven Therapeutics

Enliven Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ELVN-002
HER2 kinase inhibitor
ERBB2Phase 1HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Breast CancerJan 2027
ELVN-001
Third-generation BCR-ABL tyrosine kinase inhibitor effective against T315I mutation
BCR, ABL1Phase 1Chronic Myeloid Leukemia; CML (Chronic Myelogenous Leukemia)Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05650879ELVN-002Phase 1HER2 Mutant Non-small Cell Lung CancerOncologyJul 2026
NCT06328738ELVN-002Phase 1HER2-positive Breast CancerOncologyJan 2027
NCT05304377ELVN-001Phase 1Chronic Myeloid LeukemiaOncologyDec 2027
NCT06787144ELVN-001Phase 1CML (Chronic Myelogenous Leukemia)OncologyJan 2028

From the company's SEC filings

Cash and short-term investments of $884m on 2026-09-30; operating cash outflow about $68m a year; runway about 157 months at that burn, to Oct 2039

Press releases filed as 8-K in the last year:

Specialist investors

Held by 14 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

BCR (1) ABL1 (1) ERBB2 (1)

Companies with the same targets

Beijing Biotech Roche Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical Ascentage Pharma Group Il-Yang Pharm. Takeda Incyte Biosciences International Sàrl Novartis Taiho Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.